197,000 UK lives saved thanks to breast cancer advances
Almost 200,000 UK deaths from breast cancer have been averted since the late 80s, according to a new report.
Experts said that changes in how cancer is detected, diagnosed and treated have 'all been essential to these improvements'.
Overall, 1.5 million cancer deaths in the UK have been prevented since 1989, according to a new study predicting European cancer deaths in 2025.
But there will still be 173,300 cancer deaths overall in the UK this year, academics said.
Most cancer deaths among men in the UK in 2025 will be due to bowel; lung and prostate cancers.
While most cancer deaths among UK women will be due to bowel; lung and breast cancers.
Breast cancer deaths in the UK in 2025 will be lower than those observed in 2020 – with 11,400 women expected to die from breast cancer this year compared to 11,547 deaths in 2020.
The UK is also estimated to buck the trend when it comes to breast cancer deaths among elderly women – with deaths among over 80s attributed to breast cancer expected to rise in many European countries but fall in the UK.
Carlo La Vecchia, professor of medical statistics and epidemiology at the University of Milan in Italy, said: 'Elderly women are not covered by screening and probably are less favourably affected by the substantial advances in breast cancer management, including improvements in chemo and hormone therapy, but also in radiotherapy and surgery.
'The increased prevalence of overweight and obesity over the last few decades in most of northern and central Europe has led to an increased risk of breast cancer.
'In the elderly, this has not been counter-balanced by improved diagnosis and management. This accounts for the increased mortality in people aged 80 and over.'
In England, all women aged 50 to 71 are invited for breast cancer screening every three years.
Prof La Vecchia added: 'We estimate that between 1989 and 2025, 373,000 breast cancer deaths have been avoided in the EU and 197,000 in the UK.
'Most of these are due to improved management and therapy, but 25-30% are likely to be attributable to more widespread screening and early diagnosis.
'Given that breast cancer is now a largely curable cancer that requires modern integrated approaches, it is essential that all diagnoses of breast cancer are referred to comprehensive cancer centres, which can offer the complete range of therapies that might be required.
'As indicated by the unfavourable trends in elderly women, control of overweight and obesity is a priority now, not only for cardiovascular diseases, but also for cancer, including breast cancer.'
Commenting, Jon Shelton, Cancer Research UK's head of cancer intelligence, said: 'Breast cancer mortality rates have fallen substantially in the UK since the early 1970s, and it's extremely positive to see that trend continue.
'Breakthroughs in how we detect, diagnose and treat the disease have all been essential to these improvements.
' Studies like this showcase the power of science, and if the UK Government's upcoming national cancer plan for England prioritises reform and investment in cancer services and getting research and innovation into care, we'll see even more improvements for people affected by cancer.'
Dr Kotryna Temcinaite, head of research communications and engagement at Breast Cancer Now, said: 'It's reassuring that this research suggests that nearly 197,000 deaths from breast cancer have been avoided in the UK in the last 37 years across women of all ages.
'This could be due to a combination of increased awareness and improvements in cancer detection and treatment. But the stark reality is that 11,500 women still die from this devastating disease each year in the UK, making research into how we better diagnose and treat breast cancer more needed than ever.
'Most breast cancers (80%) occur in women aged over 50, and a quarter (25%) of cases are diagnosed in women aged 75 and over.
'It's crucial that all women regularly check their breasts and get to know their 'normal'.'
Dame Cally Palmer, national cancer director at NHS England, said: 'It's incredibly encouraging that deaths from breast cancer in the UK are continuing to fall as a result of improved early diagnosis and treatment.
'We know a third of women don't take up their invites for the scans which can detect cancer earlier, when treatment has the best chance of success – so I'd urge anyone who receives an invite to book a potentially life-saving appointment for NHS breast cancer screening.'
The new review, by a team of international researchers, also predicts small reductions in lung cancer deaths for both men and women in the UK.
But bowel cancer deaths are expected to increase from the absolute numbers in 2020, according to the new study, which has been published in the journal Annals of Oncology.
Pancreatic cancer deaths are also expected to rise, according to the estimates.
Prof La Vecchia said: 'Trends in cancer mortality continue to be favourable across Europe, however, there are a few negative indications – these include deaths from bowel cancer in people younger than 50, which have started to increase in the UK and several central and northern Europe countries, mainly due to increased prevalence of overweight and obesity in the young who are not covered by colorectal cancer screening.
'In addition, death rates from pancreatic cancer are not decreasing in the EU, and it is now the fourth cause of cancer death in Europe after lung, colorectal and breast cancer.
'Death rates from lung cancer are starting to level off but not yet to decrease in EU women. The trends in pancreatic and female lung cancer underline the urgency of implementing stricter tobacco control across Europe.'
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mirror
10 hours ago
- Daily Mirror
NHS chief gives verdict on funding settlement outlined in spending review
New NHS England boss Sir Jim Mackey insists the NHS has done "really well" in the spending review - despite a lower rate of increase than under the Tories in 2023 The new boss of the NHS has said the health service has done 'really well' out of the spending review - despite getting a worse funding settlement than under the Tories. Sir Jim Mackey gave his first major speech at the annual NHS Confed Expo conference in Manchester moments before Chancellor Rachel Reeves confirmed the health service will get a major funding squeeze. The Chancellor's spending review will mean a 3% annual budget rise, which is lower than the average 3.6% increases the NHS has received since its founding. It is also lower than the 3.3% rise seen in 2023 under the previous Conservative governments. But Sir Jim told health leaders: "The NHS has done really well relative to other parts of the public service but we all know it's never enough because of the scale of advancement, all the ambition, all things we want to do, the day-to-day cost pressures we're trying to get on top of, etc. "We're always going to be in a world where we want more money, but I think everyone's starting to accept and understand that we've got what the country can afford to give us. We really need to get better value for that money - it is broadly the equivalent of the GDP of Portugal, so it's a huge amount of money by any standards. "It's a huge amount - (the) Government has done us a really good turn compared to other parts of the public service. But it's not going to allow us all to just take our feet off the pedal and just run loose and do what we want to do in this next period, we have still got an awful lot of difficult things to do." Sir Jim succeeded previous chief executive Amanda Pritchard as the Government took direct control of NHS England, which had previously been operationally independent. Chancellor Rachel Reeves delivered her Spending Review, setting out budgets for government departments. She said she has made "tough decisions" but is rejecting "austerity". Healthcare spending generally increases to keep pace with a growing and aging population. The UK spends less on healthcare than most other European countries. The 3% rise will add up to about £30 billion a year extra by the end of the parliament. It comes as the NHS is likely to have to find the cash for above-inflation pay rises for staff and a large chunk of a £1 billion-a-year rise in drug prices ministers have promised to the pharmaceutical industry. Sir Jim acknowledged it will be a struggle for the NHS to improve 'delayed discharges' where hospitals are full of frail but otherwise well people because there is no social care places for them. He added: "Social care in local authorities won't do brilliantly in the spending review… so we will be left with what we can do as much as we can within our gift." It comes as internal Government modelling suggests that without more NHS funding Sir Keir Starmer 's government will miss a key pledge to treat 92% of patients requiring routine care within 18 weeks. The NHS constitutional standard has not been met for a decade. Sally Gainsbury, of the Nuffield Trust think tank, told the Times that "an extra 2.8 per cent in real terms will not fully cover the new demands the health service can expect each year, let alone eliminate previous problems like the waiting list backlog".
Scottish Sun
12 hours ago
- Scottish Sun
Popular jewellery set urgently recalled over ‘serious chemical risk' that can ‘damage organs and may cause cancer'
The chemical that is highly restricted in the EU RECALL ALERT Popular jewellery set urgently recalled over 'serious chemical risk' that can 'damage organs and may cause cancer' Click to share on X/Twitter (Opens in new window) Click to share on Facebook (Opens in new window) AN urgent recall has been issued for a jewellery set which contains harmful chemicals. A clover jewellery set has been recalled by the Office for Product and Safety Standards (OPSS) after finding chemicals which could cause cancer and damage organs in the jewellery. Sign up for Scottish Sun newsletter Sign up 2 The popular product is inspired by jewellery brand Van Cleef. This is not the exact product that was recalled Imported from China, the set comes in an unmarked orange box and contains a watch, necklace, bracelet and ring. The product was rejected at the border after a report marked the risk level as "serious." A statement from OPSS reads: 'The product presents a serious risk as the cadmium content is much higher than the maximum permissible limit. 'Cadmium is harmful to human health as it accumulates in the body, can damage organs and may cause cancer.' The report also confirmed that the product did not meet the requirements of the REACH Enforcement Regulations 2008. Cadmium has previously been used in various consumer and industrial products as it is known to enhance the shine and colour of pieces. However, it is now heavily restricted in the EU due to its alarming health risks. According to the UK Government: 'Exposure to cadmium for a long period of time may result in damage to the kidneys and bones and may cause cancer.' 2 The jewellery came in an unmarked orange box The clover jewellery is heavily inspired by, and likely presents a cheaper alternative to the popular luxury goods brand Van Cleef and Arpels. The product report describes the jewellery as gold in colour with a black material inset. This bears a striking resemblance to the Van Cleef products which retail for as much as £6,000. This isn't the first time products have been recalled for containing this harmful chemical. The popular Amazon brand Dervivea was also forced to recall their products earlier this month, after a report revealed that it also contained cadmium. The product listings were recalled by Amazon, with customers advised to contact the distributor they purchased the product from to request redress. Government guidance states those inhaling or ingesting cadmium are most at risk. Breathing in air with high levels of cadmium can cause 'a metallic taste in the mouth, shortness of breath, chest pain, cough and flu-like symptoms.' If you are experiencing these symptoms and are concerned about your health following prolonged exposure to cadmium, you should seek guidance from your GP or contact NHS 111.
Scottish Sun
13 hours ago
- Scottish Sun
Major change to NHS cancer screening tests as health chiefs reveal millions of women affected
Click to share on X/Twitter (Opens in new window) Click to share on Facebook (Opens in new window) MILLIONS of women will be offered NHS cervical screening less often under radical new changes. Those under 50 will only be called forward every five years - instead of three like they currently are. Sign up for Scottish Sun newsletter Sign up 3 Health chiefs say new testing approach is backed by clinical evidence and 'more personalised' Credit: Getty The plans, announced on Tuesday by NHS England, are said to be "in line" with "major" clinical evidence that suggests just as many cancer cases would be detected. Health chiefs said the changes would enable 'millions of women and people with a cervix in England to benefit from more personalised cervical screening'. "This new guidance is good news for those at low risk because they will no longer need to go for cervical screening as often," Athena Lamnisos, CEO of The Eve Appeal, said. Scotland and Wales have already introduced this protocol, which will start in England from July 1. Under the NHS screening system, which replaced smears, cells are tested for the Human Papillomavirus (HPV), which causes almost all cervical cancer. Traditional smear tests, also known as pap smears, looked for all abnormal cells directly but were less accurate than the new cervical screening tests. Currently, women aged 25 to 49 in England are offered such checks every three years, with screening every five years for those aged 50 to 64. If HPV is found, checks are then repeated each year, with further investigations if any cell abnormalities are found. More regular screening is also offered to those with a recent history of HPV. Under the new system, checks on those with positive results will remain annual. Cervical cancer could be eradicated as HPV vaccine slashes 90% of cases But the standard gap for those who test negative will extend from three years to five for women aged 25 to 49. This is because research shows they are at very low risk of cervical cancer for the next ten years and can safely wait longer to be screened again. This puts it in line with the gap for older women, in a similar approach to that adopted by Australia, the Netherlands and Sweden. Under the NHS plan, if a woman aged between 25 and 49 had a negative result, but previously had a positive test, they would still get a test three years later. Health chiefs said the new approach was more 'personalised' than previous approaches. Screening will also continue to be offered to trans men if they still have a cervix. 3 3 A DIY cervical screening test that women can do at home could be rolled out on the NHS Michelle Mitchell, chief executive of Cancer Research UK, said: 'We welcome this change to cervical screening in England, which is the result of years of vital research to make screening more effective and has shown it is safe to extend the time between tests. 'Screening, alongside the roll out of the HPV vaccine – which Cancer Research UK scientists helped develop – have seen cervical cancer rates drop by around a quarter since the early 1990s, and we look forward to even more progress. 'If you notice any unusual changes for you, do not wait for a screening invitation – speak to your doctor.' DIY cancer check Cervical screening programmes and HPV vaccines have reduced rates and save 5,000 lives each year. Around 3,300 new cases are identified annually - that's around nine every day. And one in 130 women in the UK will be diagnosed with cervical cancer in their lifetime. Earlier this year, the NHS announced an at-home cervical screening tests could be rolled out in England from early 2026 for free. A new trial, known as the King's College London YouScreen trial, is the biggest to date and shows how the DIY kit can boost the numbers of women getting screened. Figures show that cervical screening uptake is declining, with nearly a third of women in England - particularly younger women - not taking up their most recent test. Experts say women may refuse testing due to a lack of convenient appointments, embarrassment and worries about the test causing pain. The new plan includes expanding the "ping and book" service, which sends reminders for screening appointments.
